

# Pneumococcal conjugate vaccine trial: PNEUVAC TRIAL

<b>Submission date</b> 22/07/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/07/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 01/12/2016	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

The pneumococcus bacterium is a leading problem in HIV-infected adults. It is the leading cause of bacterial meningitis and a principal cause of bloodstream infection/blood poisoning (pneumococcal disease). HIV-infected individuals who have had one attack of serious pneumococcal infection have a 1 in 4 chance of a further attack in the next 12 months. Disease is often severe and death occurs in 20% of cases. Vaccines for preventing pneumococcal disease have been available for over 90 years, based on vaccinating with the outer lining of the bacterium, the capsule. The vaccine recommended for adults contains capsule for 23 types of pneumococci (23-valent). There are over 90 types but most disease is caused by these 23 types. Immunisation with the 23-valent vaccine was tested in HIV-infected adults in Uganda, but the vaccine failed to provide protection. A second generation of pneumococcal vaccines has been licensed for use in children. As the vaccine was developed primarily for use in children, information on the role of the vaccine in adults and particularly HIV-infected adults is lacking. The aim of this study is to test the effectiveness of the new vaccine to prevent pneumococcal disease in HIV-infected adults.

### Who can participate?

Patients aged over 15 who have recovered from a serious pneumococcal infection and are willing to have an HIV test.

### What does the study involve?

Participants are randomly allocated to receive either the active vaccine or a placebo (dummy) injection. The vaccination consists of two injections given into the upper arm, 4-6 weeks apart. Participants are followed-up every three months. If a participant becomes unwell they are requested to attend the Queen Elizabeth Central Hospital to be investigated for pneumococcal infection. Transport costs are provided for routine visits and those requested by the Doctor. Blood tests are carried out at routine visits and when participants are unwell – this will be 10-25 ml of blood. An HIV test is performed on the first blood sample. The results of the HIV test are available to the participants. In addition to blood tests a sample from the nose is taken at each visit to investigate for the presence of the pneumococcus in the nose.

What are the possible benefits and risks of participating?

Benefits include increased access to clinical services both for routine follow up of HIV and more rapid assessment of acute illness episodes, with greater access to diagnostic services than available routinely within the hospital. The study will encourage uptake of HIV test results with appropriate support and thereby increase access to HIV services and beneficial treatments. Risks include possible side effects from vaccination, although work to date suggests this is a very safe vaccine with low rates of reaction. There will be discomfort associated with the blood sampling and nasal swabbing, although these will be transitory. Because a great deal of research going on is HIV associated, there is the potential for individuals to be identified as HIV-infected by association with the study. Confidentiality and integration of services into routine care will minimize this risk.

Where is the study run from?

Queen Elizabeth Central Hospital, Blantyre, Malawi

When is the study starting and how long is it expected to run for?

February 2003 to October 2007

Who is funding the study?

The Wellcome Trust (UK)

Who is the main contact?

Prof. Neil French

neil.french@lshtm.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Mr Neil French

### Contact details

Malawi-Liverpool-Wellcome Trust Labs

Blantyre

Malawi

Box 3009

+265 (0)9 207898

neil.french@lshtm.ac.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00371878

## Secondary identifying numbers

061230

# Study information

## Scientific Title

Investigation of the humoral immune response to pneumococcal polysaccharides and the role of a conjugate pneumococcal vaccine in secondary prevention of invasive pneumococcal disease in human immunodeficiency virus (HIV)-infected Africans

## Acronym

PNEUVAC

## Study objectives

Efficacy of a seven-valent pneumococcal conjugate vaccine to prevent recurrent episodes of vaccine serotype invasive pneumococcal disease (IPD) in a primarily human immunodeficiency virus (HIV)-infected adult population.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

1. University of Malawi, College of Medicine Research and Ethics Committee, 12/01/2001, ref: P. 99/00/101
2. Liverpool School of Tropical Medicine Research and Ethics Committee, 20/12/2000, ref: 00.60

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Other

## Study type(s)

Prevention

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Invasive pneumococcal disease in HIV-infected Africans

## Interventions

Participants are recruited from individuals who are convalescing from a known invasive pneumococcal disease event. They are randomised into two arms in a 1:1 ratio to receive two doses of vaccine one month apart. In the active arm the vaccine is Prevenar® (Wyeth pharmaceuticals seven-valent pneumococcal conjugate vaccine with a CRM carrier protein). In the control arm participants receive a matching saline placebo.

Vaccine is given as a 0.5 ml injection into the non-dominant deltoid muscle. Participants are followed up at three-monthly intervals and encouraged to attend the hospital when sick for evaluation of their illness. Individuals will be followed as long as they remain alive and within the study area until the follow-up censor date which was set at 31st October 2007. Total follow up is 798 person years with a median follow up time of 1.24 years [Range 2 days to 4.66 years].

### **Intervention Type**

Biological/Vaccine

### **Primary outcome measure**

Vaccine serotype invasive pneumococcal disease

### **Secondary outcome measures**

1. All invasive pneumococcal disease death
2. All cause pneumonia

### **Overall study start date**

28/02/2003

### **Completion date**

31/10/2007

## **Eligibility**

### **Key inclusion criteria**

1. Confirmed case of IPD discharged from hospital
2. Resident of Blantyre and its immediately neighbouring districts
3. Willing to attend Queen Elizabeth Central Hospital (QECH) when sick
4. Aged over 15 years, either sex
5. Willing to have HIV testing performed on stored serum

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Both

### **Target number of participants**

320

### **Key exclusion criteria**

1. Pregnancy
2. Previous pneumococcal vaccine
3. Active acute systemic illness - following recovery participant may be recruited
4. Past hypersensitivity reaction to vaccination
5. Bed-ridden or life expectancy judged to be less than three months

**Date of first enrolment**

28/02/2003

**Date of final enrolment**

31/05/2007

## **Locations**

**Countries of recruitment**

Malawi

**Study participating centre**

**Malawi-Liverpool-Wellcome Trust Labs**

Blantyre

Malawi

Box 3009

## **Sponsor information**

**Organisation**

University of Liverpool (UK)

**Sponsor details**

Senate House

Research Support

Abercromby Square

Liverpool

England

United Kingdom

L69 3BX

**Sponsor type**

University/education

**Website**

<http://www.liv.ac.uk/>

**ROR**

<https://ror.org/04xs57h96>

# Funder(s)

## Funder type

Charity

## Funder Name

Wellcome Trust (UK) (grant ref: 061230)

## Alternative Name(s)

## Funding Body Type

Private sector organisation

## Funding Body Subtype

International organizations

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	04/03/2010		Yes	No
<a href="#">Results article</a>	results	01/09/2016		Yes	No